Hepatocellular Carcinoma Risk Scores: Ready to Use in 2015?

Overview

Journal Hepat Oncol

Date 2018 Sep 8

PMID 30190979

Citations 1

Authors

Chien-Jen Chen

Mei-Hsuan Lee

Jessica Liu

Hwai-I Yang

Affiliations

Soon will be listed here.

Citing Articles

Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population.

Wu H, Yang H, Wang Q, Chen C, Santella R Carcinogenesis. 2017; 38(10):1021-1028.

PMID: 28981677 PMC: 5862336. DOI: 10.1093/carcin/bgx078.

References

Fontana R, Dienstag J, Bonkovsky H, Sterling R, Naishadham D, Goodman Z . Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut. 2010; 59(10):1401-9. PMC: 3740000. DOI: 10.1136/gut.2010.207423. View

Huang Y, Jen C, Yang H, Lee M, Su J, Lu S . Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol. 2011; 29(27):3643-50. PMC: 4874144. DOI: 10.1200/JCO.2011.36.2335. View

Lee M, Yang H, Lu S, Jen C, You S, Wang L . Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma. Int J Cancer. 2014; 135(5):1119-26. DOI: 10.1002/ijc.28753. View

Wong V, Chan S, Mo F, Chan T, Loong H, Wong G . Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010; 28(10):1660-5. DOI: 10.1200/JCO.2009.26.2675. View

Yuen M, Tanaka Y, Fong D, Fung J, Wong D, Yuen J . Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2008; 50(1):80-8. DOI: 10.1016/j.jhep.2008.07.023. View

Chen C, Yu M, Liaw Y . Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol. 1998; 12(9-10):S294-308. DOI: 10.1111/j.1440-1746.1997.tb00513.x. View

Lee M, Yang H, Yuan Y, LItalien G, Chen C . Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol. 2014; 20(28):9270-80. PMC: 4110557. DOI: 10.3748/wjg.v20.i28.9270. View

Yang H, Yeh S, Chen P, Iloeje U, Jen C, Su J . Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst. 2008; 100(16):1134-43. PMC: 2518166. DOI: 10.1093/jnci/djn243. View

Wong G, Chan H, Chan H, Tse P, Tse Y, Mak C . Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology. 2013; 144(5):933-44. DOI: 10.1053/j.gastro.2013.02.002. View

10.

Yang H, Sherman M, Su J, Chen P, Liaw Y, Iloeje U . Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol. 2010; 28(14):2437-44. DOI: 10.1200/JCO.2009.27.4456. View

11.

Lee M, Yang H, Liu J, Batrla-Utermann R, Jen C, Iloeje U . Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology. 2013; 58(2):546-54. DOI: 10.1002/hep.26385. View

12.

Lee M, Lu S, Yuan Y, Yang H, Jen C, You S . Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. PLoS One. 2014; 9(5):e94760. PMC: 4011690. DOI: 10.1371/journal.pone.0094760. View

13.

Lok A, Seeff L, Morgan T, Di Bisceglie A, Sterling R, Curto T . Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2008; 136(1):138-48. PMC: 3749922. DOI: 10.1053/j.gastro.2008.09.014. View

14.

Yang H, Lee M, Liu J, Chen C . Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia. World J Gastroenterol. 2014; 20(20):6244-51. PMC: 4033462. DOI: 10.3748/wjg.v20.i20.6244. View

15.

Ghany M, Lok A, Everhart J, Everson G, Lee W, Curto T . Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology. 2009; 138(1):136-46. PMC: 2813393. DOI: 10.1053/j.gastro.2009.09.007. View

16.

Chen C, Chen D . Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology. Hepatology. 2002; 36(5):1046-9. DOI: 10.1053/jhep.2002.37084. View

17.

Abu Dayyeh B, Yang M, Fuchs B, Karl D, Yamada S, Sninsky J . A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology. 2011; 141(1):141-9. PMC: 3129453. DOI: 10.1053/j.gastro.2011.03.045. View

18.

Lee M, Yang H, Lu S, Jen C, Yeh S, Liu C . Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol. 2010; 28(30):4587-93. DOI: 10.1200/JCO.2010.29.1500. View

19.

Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T . Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001; 357(9262):1069-75. DOI: 10.1016/S0140-6736(00)04258-6. View

20.

Chen C, Yang H, Iloeje U . Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009; 49(5 Suppl):S72-84. DOI: 10.1002/hep.22884. View